IBDEI0YZ ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17376,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17376,1,1,0)
 ;;=1^V65.49
 ;;^UTILITY(U,$J,358.3,17376,1,8,0)
 ;;=8^Medication Counseling
 ;;^UTILITY(U,$J,358.3,17376,2)
 ;;=^303471
 ;;^UTILITY(U,$J,358.3,17377,0)
 ;;=V66.2^^111^1083^2
 ;;^UTILITY(U,$J,358.3,17377,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17377,1,1,0)
 ;;=1^V66.2
 ;;^UTILITY(U,$J,358.3,17377,1,8,0)
 ;;=8^Chemotherapy Convalescen
 ;;^UTILITY(U,$J,358.3,17377,2)
 ;;=^295568
 ;;^UTILITY(U,$J,358.3,17378,0)
 ;;=V76.10^^111^1083^11
 ;;^UTILITY(U,$J,358.3,17378,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17378,1,1,0)
 ;;=1^V76.10
 ;;^UTILITY(U,$J,358.3,17378,1,8,0)
 ;;=8^Screen Mal Neopl, Breast,Unsp
 ;;^UTILITY(U,$J,358.3,17378,2)
 ;;=^317968
 ;;^UTILITY(U,$J,358.3,17379,0)
 ;;=V76.2^^111^1083^9
 ;;^UTILITY(U,$J,358.3,17379,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17379,1,1,0)
 ;;=1^V76.2
 ;;^UTILITY(U,$J,358.3,17379,1,8,0)
 ;;=8^Screen Mal Neop-Cervix
 ;;^UTILITY(U,$J,358.3,17379,2)
 ;;=^295653
 ;;^UTILITY(U,$J,358.3,17380,0)
 ;;=V76.41^^111^1083^10
 ;;^UTILITY(U,$J,358.3,17380,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17380,1,1,0)
 ;;=1^V76.41
 ;;^UTILITY(U,$J,358.3,17380,1,8,0)
 ;;=8^Screen Mal Neop-Rectum
 ;;^UTILITY(U,$J,358.3,17380,2)
 ;;=^295655
 ;;^UTILITY(U,$J,358.3,17381,0)
 ;;=V26.33^^111^1083^7
 ;;^UTILITY(U,$J,358.3,17381,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17381,1,1,0)
 ;;=1^V26.33
 ;;^UTILITY(U,$J,358.3,17381,1,8,0)
 ;;=8^Genetic Counseling
 ;;^UTILITY(U,$J,358.3,17381,2)
 ;;=^332865
 ;;^UTILITY(U,$J,358.3,17382,0)
 ;;=V58.11^^111^1083^6
 ;;^UTILITY(U,$J,358.3,17382,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17382,1,1,0)
 ;;=1^V58.11
 ;;^UTILITY(U,$J,358.3,17382,1,8,0)
 ;;=8^Encounter for Chemotherapy
 ;;^UTILITY(U,$J,358.3,17382,2)
 ;;=^332869
 ;;^UTILITY(U,$J,358.3,17383,0)
 ;;=V58.12^^111^1083^5
 ;;^UTILITY(U,$J,358.3,17383,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17383,1,1,0)
 ;;=1^V58.12
 ;;^UTILITY(U,$J,358.3,17383,1,8,0)
 ;;=8^Enc for Antineoplastic Immunother
 ;;^UTILITY(U,$J,358.3,17383,2)
 ;;=^341508
 ;;^UTILITY(U,$J,358.3,17384,0)
 ;;=188.9^^111^1084^2
 ;;^UTILITY(U,$J,358.3,17384,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17384,1,1,0)
 ;;=1^188.9
 ;;^UTILITY(U,$J,358.3,17384,1,8,0)
 ;;=8^Malig Neo Bladder,Unspec Part
 ;;^UTILITY(U,$J,358.3,17384,2)
 ;;=^267253
 ;;^UTILITY(U,$J,358.3,17385,0)
 ;;=233.7^^111^1084^1
 ;;^UTILITY(U,$J,358.3,17385,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17385,1,1,0)
 ;;=1^233.7
 ;;^UTILITY(U,$J,358.3,17385,1,8,0)
 ;;=8^Malig Neo Bladder In Situ
 ;;^UTILITY(U,$J,358.3,17385,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,17386,0)
 ;;=185.^^111^1084^12
 ;;^UTILITY(U,$J,358.3,17386,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17386,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,17386,1,8,0)
 ;;=8^Malig Neo Prostate
 ;;^UTILITY(U,$J,358.3,17386,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,17387,0)
 ;;=189.0^^111^1084^10
 ;;^UTILITY(U,$J,358.3,17387,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17387,1,1,0)
 ;;=1^189.0
 ;;^UTILITY(U,$J,358.3,17387,1,8,0)
 ;;=8^Malig Neo Kidney
 ;;^UTILITY(U,$J,358.3,17387,2)
 ;;=^73523
 ;;^UTILITY(U,$J,358.3,17388,0)
 ;;=189.1^^111^1084^13
 ;;^UTILITY(U,$J,358.3,17388,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17388,1,1,0)
 ;;=1^189.1
 ;;^UTILITY(U,$J,358.3,17388,1,8,0)
 ;;=8^Malig Neo Renal Pelvis
 ;;^UTILITY(U,$J,358.3,17388,2)
 ;;=^267264
 ;;^UTILITY(U,$J,358.3,17389,0)
 ;;=189.2^^111^1084^16
 ;;^UTILITY(U,$J,358.3,17389,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17389,1,1,0)
 ;;=1^189.2
 ;;^UTILITY(U,$J,358.3,17389,1,8,0)
 ;;=8^Malig Neo Ureter
